2026-08-20 · Dartmouth College
Chris Snyder Discusses FDA Drug Repurposing and Market Incentives
with Christopher (Chris) Snyder, Joel Z. and Susan Hyatt Professor in the Economics Department at Dartmouth College — Dartmouth College

Generic drugs often miss opportunities for secondary uses after patent expiration because manufacturers lack a financial incentive, says Christopher Snyder, a professor at Dartmouth College, discussing the FDA's exploration of drug repurposing. Snyder explains how generic drugs often miss opportunities for secondary uses due to a lack of financial motivation for manufacturers after patent expiration. He also highlights the work of the Market Shaping Accelerator, a collaborative initiative aimed at enhancing innovation in public health and addressing market failures.
Related coverage
Chris Snyder Discusses FDA Drug Repurposing and Market Incentives
FDA Explores Drug Repurposing to Boost Market Incentives, Says Dartmouth Economist
In a recent episode of the Health Policy Podcast, Christopher Snyder, a Hyatt Professor in the Economics Department at Dartmouth College, discussed the potential of drug repurposing and the economic incentives involved. Snyder, who is also a faculty co-director of the Market Shaping Accelerator, emphasized the need for innovative approaches to increase the use of existing generic drugs for new medical purposes.
Snyder explained that drug repurposing involves taking an already approved medication and exploring its efficacy for different health conditions. He cited aspirin as a classic example, originally developed for pain relief but later found to be effective in preventing heart attacks. Snyder noted that many generic drugs could have untapped therapeutic uses, with estimates suggesting that hundreds of potential treatments remain unexplored.
The conversation highlighted a significant challenge in the pharmaceutical industry: the lack of financial incentives for repurposing generic drugs. Snyder explained that while branded drugs benefit from patent protections that encourage research into secondary uses, generic drugs face a different reality. Once a drug goes off patent, the financial motivation to explore new applications diminishes. "Once a drug goes off patent, it turns out you can actually get a patent on second uses, but you can't monetize it," Snyder said.
Snyder elaborated on the economic principles at play. Branded pharmaceutical companies have a vested interest in discovering new uses for their products, as these can expand their market and revenue. In contrast, generic drug manufacturers do not have the same incentives. The result is a significant drop in research into repurposed uses for generics as they approach patent expiration.
The FDA has recently sought public comments on advancing drug repurposing initiatives. Snyder indicated that the FDA is looking for input from various stakeholders, including economists and clinicians, to identify promising areas for investment. The Market Shaping Accelerator has responded to this call, proposing policy changes that could enhance incentives for repurposing generic medications.
Snyder pointed out that the costs associated with clinical trials for repurposed drugs could be lower for generics since their safety has already been established. This could facilitate quicker and more cost-effective research into new applications for existing drugs.
The Market Shaping Accelerator, co-founded by Snyder, aims to address these challenges by advocating for innovative funding mechanisms. The organization seeks to create market-based incentives that reward successful drug development rather than merely funding attempts. Snyder described the concept of "pull funding," which incentivizes companies to develop new products by promising financial rewards upon successful completion.
Snyder also discussed the barriers to innovation in the pharmaceutical sector. He noted that the lengthy and costly process of bringing a new drug to market can deter investment, particularly in areas with limited commercial potential. He emphasized the need for public funding to bridge gaps in markets where private investment is insufficient.
The Market Shaping Accelerator has initiated an innovation challenge to crowdsource ideas for effective market incentives. Snyder mentioned that the organization received 190 submissions and is currently working with three finalists to develop their proposals further.
For more information about the Market Shaping Accelerator and its initiatives, interested parties can visit their website at marketshapingaccelerator.org. Snyder's insights underscore the importance of fostering an environment conducive to drug repurposing, which could lead to significant advancements in public health.
Interview Q&A
Q&A: Chris Snyder Discusses FDA Drug Repurposing and Market Incentives
Health Policy Podcast: Chris Snyder Discusses FDA Drug Repurposing and Market Incentives
Q: Can you tell us about yourself and your role at Dartmouth College?
A: I teach economics at Dartmouth College and serve as one of the faculty co-directors of the Market Shaping Accelerator, a policy organization in collaboration with the University of Chicago and the Center for Global Development.
Q: What does "repurposed uses" mean in the context of the FDA?
A: Repurposed uses refer to drugs that were initially developed for one purpose but later found to be effective for another. For example, aspirin was originally for pain relief but later discovered to help prevent heart attacks.
Q: Why are there missed opportunities in drug repurposing?
A: For branded drugs, companies have incentives to find repurposed uses since they can profit from them. However, generic drugs lose these incentives once they go off patent, making it less likely for companies to invest in discovering new uses.
Q: What are the financial disincentives for drug companies regarding repurposing?
A: The costs of clinical trials are high, and the chance of success is low. Once a drug goes generic, any company can sell it, making it difficult to monetize new uses, which discourages investment in repurposing.
Q: What is the FDA seeking from public comments on drug repurposing?
A: The FDA is looking for input from economists, clinicians, and scientists on potential areas for drug repurposing and suggestions for policies that could encourage this practice.
Q: Why focus on generics for drug repurposing?
A: Generics have already been proven safe for their initial uses, which can lower the costs of further clinical trials for new indications. This makes repurposing generics a more feasible option.
Q: What is the Market Shaping Accelerator's mission?
A: The Market Shaping Accelerator aims to solve significant social problems through innovation. We focus on creating market-based incentives to encourage the development of solutions for neglected areas where commercial markets fail.
Q: Can you explain the difference between push funding and pull funding?
A: Push funding involves providing grants to support early-stage ideas, while pull funding offers financial rewards for successful innovations. Pull funding incentivizes teams to produce marketable solutions.
Q: What are some barriers to innovation in pharmaceuticals?
A: Barriers include high costs of clinical trials, uncertainty about success rates, and the challenge of ensuring that inventors can profit from their innovations. Market failures can also hinder investment in socially beneficial innovations.
Q: How can people learn more about your work?
A: People can visit the Market Shaping Accelerator's website for information on our projects, publications, and details about our innovation challenge, which received 190 submissions.
Q: What are some examples of successful market-based incentives?
A: Examples include prize competitions like the XPRIZE and advanced market commitments, which reward successful innovations based on their market performance.
Q: What role does public funding play in innovation?
A: Public funding helps bridge gaps in areas where commercial incentives are lacking, such as public health and climate mitigation, encouraging investment in innovations that benefit society.
Q: How does the Market Shaping Accelerator plan to advance drug repurposing?
A: We are proposing policies that could be adopted by agencies like Medicare and Medicaid to boost incentives for repurposing generic drugs, addressing the barriers currently faced in this area.
Key questions
What does drug repurposing mean in the context of the FDA?
Drug repurposing refers to the process of finding new uses for existing drugs that were originally developed for a specific condition. For example, aspirin was initially discovered for pain relief but was later found to be effective in preventing second heart attacks.
Why are there missed opportunities for repurposing generic drugs?
Generic drugs often lack financial incentives for repurposing because once a drug goes off patent, companies cannot monetize new uses effectively. This results in fewer repurposed uses as the market incentive diminishes.
What are the challenges faced by pharmaceutical companies in drug repurposing?
Pharmaceutical companies face high costs associated with clinical trials and the uncertainty of success rates. For generics, the lack of profit potential after patent expiration makes repurposing less appealing.
What is the Market Shaping Accelerator?
The Market Shaping Accelerator is a policy organization co-directed by Chris Snyder, focused on solving social problems through innovation and market-based incentives, particularly in health policy.
How does the FDA seek public input on drug repurposing?
The FDA issues calls for public comment to gather insights from economists, clinicians, and scientists on potential areas for drug repurposing and to inform their policies.
What are some proposed incentives for drug repurposing?
Proposed incentives include pull funding mechanisms that reward successful drug repurposing efforts, thereby encouraging companies to invest in research for generic drugs with potential new uses.
What role does innovation play in addressing social problems?
Innovation can provide significant social benefits by solving complex problems efficiently. The Market Shaping Accelerator aims to leverage innovation to create a multiplier effect, generating more social good from investment.
Key takeaways
- “The idea is that often a drug that was initially discovered for one use or another actually has a second life as a different use.”
- “There's a study that suggests that there might be hundreds as many as eight hundred missing treatments of generics.”
- “The thing is that that incentive doesn't hold for generic drugs.”
- “Once a drug goes off patent, it turns out you can actually get a patent on second uses, but you can't monetize it.”
- “The costs of the clinical trials are going to be lower for a generic because it's already been proven safe for the other use.”
- “Our goal is like, how can we solve big social problems that seem intractable?”
About the guest

Joel Z. and Susan Hyatt Professor in the Economics Department at Dartmouth College — Dartmouth College
Christopher Snyder is the Joel Z. and Susan Hyatt Professor in the Economics Department at Dartmouth College. He specializes in the economics of markets, contracting, and health. He is a Research Associate in the National Bureau of Economic ResearchOpens in a new window, Faculty Co-director of the Market Shaping Accelerator, and Treasurer of the Industrial Organization Society. He received his Ph.D. in Economics from the Massachusetts Institute of Technology in 1994. He lives in Hanover, New Hampshire, with his wife, Maura Doyle, who is a senior lecturer in the Economics Department.
Full transcript
Show full transcriptHide transcript
Filed under
More on FDA approval, Right to Try and patient access
FDA approval, Right to Try and patient access →
- Patient's Rising's Terry Wilcox: The gap between FDA approval and patient access for Alzheimer’s treatments
- The Taxpayers Protection Alliance’s Ross Marchand Discusses FDA Drug Approval Challenges and Solutions
- Right to Try 2.0: Jennifer and Maya Reinhardt on cystic fibrosis and access to experimental treatments
- Right to Try 2.0: Brian Norman of the Goldwater Institute on individualized treatments and patient access
Related episodes
- The Taxpayers Protection Alliance’s Ross Marchand Discusses FDA Drug Approval Challenges and Solutions
- Drug prices: Eric Maus on the real cost of government intervention
- The GLP-1 Bridge Program: Price Fixing vs. Free Market Healthcare
- Right to Try 2.0: Brian Norman of the Goldwater Institute on individualized treatments and patient access
